La semaglutida, junto con otros frmacos de su clase como liraglutida o tirzepatida , forma parte del grupo de los agonistas del receptor GLP-1 , diseados para imitar una hormona intestinal que genera sensacin de saciedad y reduce el apetito, adems de regular el azcar en sangre
It focuses on the mechanism of action of GLP-1R in pancreatic islet -cells, -cells and -cells, as well as its effects on the central nervous system and gastrointestinal tract
Intriguingly, overexpression of apoC-III has been shown to decrease intestinal secretion of dietary triglycerides into lymph due to impaired lipid uptake into enterocytes, and impaired esterification capacity to form triglyceride in the mucosa ( There is a low concentration of free (i agonists, fenofibrate and rosiglitazone, on biomarkers of lipid and glucose metabolism in healthy nondiabetic volunteers
These combined effects result in several clinically meaningful outcomes: Improved blood sugar control For people with type 2 diabetes, GLP-1s help reduce both fasting and post-meal blood glucose, often allowing for a reduction in other medications
